RET fusion-positive NSCLC patients benefit from targeted therapies like Retevmo and Gavreto, recommended by NCCN guidelines for first-line treatment. Gavreto demonstrated a 57% overall response rate ...

The 2026 NCCN Bladder Cancer Guidelines incorporate the IBCG five-factor model, introducing standardized risk stratification for intermediate-risk NMIBC. For decades, heterogeneity in ...

PLYMOUTH MEETING, PA [February 17, 2026] — The National Comprehensive Cancer Network ® (NCCN ®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Pediatric Soft ...

The National Comprehensive Cancer Network ® (NCCN ®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Pediatric Soft Tissue Sarcomas. This is the 7th NCCN ...

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk ...

Besremi is now a Category 1 preferred treatment for high-risk ET patients with inadequate response to existing therapies, according to NCCN guidelines. The NCCN's inclusion of Besremi reflects strong ...

Distress management guideline updates aim to destigmatize the psychosocial effects of cancer and treatment, and encourage patients with cancer to seek help.

ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate ...

The MarketWatch News Department was not involved in the creation of this content.-- Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with pap ...

Experts discuss why and how to navigate information overload and counter misinformation so that people with cancer can make well-informed decisions about their care. "We must provide patients with ...